ACTUATE THERAPEUTICS Business Summary

Actuate Therapeutics, Inc. (ACTU) is a clinical-stage biopharmaceutical company primarily focused on the development of elraglusib (9-ING-41), a first-in-class small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β). The company’s business model is currently pre-revenue, with its primary value generation derived from advancing its clinical pipeline toward regulatory approval or strategic licensing and co-development partnerships. Actuate’s lead candidate is being evaluated for high-impact, difficult-to-treat malignancies, including metastatic pancreatic cancer, where Phase 2 data has demonstrated significant survival benefits, and refractory melanoma via a newly initiated oral tablet program. In the competitive landscape, Actuate contends with oncology-focused firms such as Jazz Pharmaceuticals, Moderna, and Kite Pharma. The company occupies a distinct market niche by specifically targeting the GSK-3β pathway to reverse chemoresistance and modulate the tumor microenvironment, offering a differentiated mechanism of action compared to traditional kinase inhibitors. The leadership team is anchored by President and CEO Daniel M. Schmitt, who has led the company since its 2015 inception and brings over two decades of experience in life sciences management. The founding team includes Chief Operating Officer Andrew P. Mazar, Ph.D., a veteran drug developer with extensive expertise in translational medicine, while financial operations are overseen by CFO Paul J. Lytle. Actuate’s strategic oversight is provided by a board of directors chaired by Aaron Fletcher, Ph.D., and includes industry veterans such as Dan Zabrowski and Todd Thomson. The company maintains strong institutional backing from notable investors including Bios Equity Partners, Kairos Ventures, and Voss Capital, supporting its transition to a Nasdaq-listed entity following its 2024 initial public offering.